Stroke prevention in AF: Implementing the NICE guidelines
|
|
- Gilbert Harris
- 8 years ago
- Views:
Transcription
1 Stroke prevention in AF: Implementing the NICE guidelines Dr Hamsaraj Shetty, B.Sc, MBBS, FRCP (London & Edinburgh) Consultant Physician & Honorary Senior Lecturer, University Hospital of Wales & Cardiff University
2 Disclosures & acknowledgements I have been an advisor for BMS, Bayer, Boehringer Ingleheim,& Pfizer from whom I have received honoraria. I would like to thank Boehringer Ingleheim for supporting a Research Nurse, who has collected the primary care AF data I would also like to thank Bayer who have provided me some of the data
3 Key points The importance of AF as a risk factor Identification & Risk stratification The guidelines Choice of drugs Prescribing NOACs: practical aspects
4 AF& Stroke AF is the most common arrhythmia Incidence is increasing Prevalence of AF is high & rising ( Estimate % ) An important risk factor for stroke More likely to cause severe & fatal strokes
5 Atrial Fibrillation in Ischemic Stroke: Clinical Outcomes Risk of death at 30 days Stroke in AF patients Stroke in non-af patients 22.3% 10.2%; P< Risk of death 1 year 37.1% 19.5%; P<0.0001) Death or disability at discharge 69.7% 54.7%; P<0.0001) Risk of intracranial hemorrhage (any type) with thrombolysis 16.5% 11.6%; relative risk, 1.42; 95% CI, ) Saposnik et al, Stroke. 2013;44:99-104
6 AF & Ischemic Stroke: functional outcomes at discharge (Modified Rankin Scale) Saposnik et al, Stroke. 2013;44:99-104
7 Key points The importance of AF as a risk factor Identification & Risk stratification The guidelines Choice of drugs Prescribing NOACs: practical aspects
8 Stroke prevention in AF: the problem 18% of AF remains undiagnosed 93% of AF are nonvalvular; 87% of whom are eligible for anticoagulation Anticoagulants are underused
9 AF Ischaemic Stroke Inpatients per 1000 AF QOF Patients (HES Intersect Analysis for Inpatients with a Primary or Secondary Diagnosis of Ischaemic Stroke with Atrial Fibrillation) Pre Stroke Diagnosis of AF At or Post Spell Diagnosis of AF All AF istroke per 1000 AF QOF English CCGs NHS Eastern Cheshire CCG NHS Halton CCG NHS Knowsley CCG NHS Liverpool CCG NHS South Cheshire CCG NHS South Sefton CCG NHS Southport and Formby CCG NHS St Helens CCG NHS Vale Royal CCG NHS Warrington CCG NHS West Cheshire CCG NHS Wirral CCG Job Bag: L.GB Date of Prep: Jan Primary & Secondary Diagnosed AF-iStroke Patients per 1000 AF QOF Patients 9
10 Use of antithrombotics in AF GARFIELD registry, Adapted from Kakkar et al., Plos One 2013
11 Use of OAC for AF in South East Wales Total: 775 patients, 5 surgeries Anjum T, Welsh M, Shetty H, 2014
12 Use of OAC for AF in South East Wales Mean age: 76 years (range years) 353/775 females (45.5%) 443/775 patients (57.2%) were on OAC The median time in therapeutic range (TTR): 79.6% (TTR range %) Anjum T, Welsh M, Shetty H, 2014
13 Use of OAC for AF in South East Wales Only 18 patients (4%) had TTR <60% 5/443 (1.1%) had major haemorrhages requiring hospitalisation No deaths on OACs Anjum T, Welsh M, Shetty H, 2014
14 Use of OAC for AF in South East Wales: Reasons for not prescribing OAC 332/775 (42.8%) patients in AF were not on OAC 169/332 (50.9%) of these patients were high-risk : CHADS2 score >2 OAC not used in eligible patients because: previous haemorrhages, malignancy, poor compliance, low platelets, erratic INR control or patient refusal 96/169 (57%) eligible patients were denied OAC due to falsely perceived contraindications e.g. old age, falls risk, dementia, active life style Anjum T, Welsh M, Shetty H, 2014
15 AF the challenge remains! Many patients remain undetected in the community Need to identify & risk stratify all AF patients All eligible patients should be anticoagulated unless there are genuine contraindications.
16 Opportunistic screening Palpate pulse in people presenting with breathlessness/dyspnoea palpitations syncope/dizziness chest discomfort An irregular pulse sensitive to the presence of AF PPV greatest in those over 75 years old The NPV of a regular pulse very high (>96%)
17 Stroke risk assessment with CHA 2 DS 2 -VASc CHA 2 DS 2 -VASc criteria Congestive heart failure/ left ventricular dysfunction Score Hypertension 1 Age 75 yrs 2 Diabetes mellitus 1 Stroke/transient ischaemic attack/te Vascular disease (prior myocardial infarction, peripheral artery disease or aortic plaque) Age yrs 1 Sex category (i.e. female gender) CHA 2 DS 2 -VASc total score Rate of stroke/other TE (%/year)* Theoretical rates without therapy: assuming that warfarin provides a 64% relative reduction in TE risk (2.7% ARR), based on Hart et al. TE = thromboembolism 1 Lip GYH et al. Stroke 2010;41: Hart RG et al. Ann Intern Med 2007;146: TE = thromboembolism DBG2919 September 2011
18 Key points The importance of AF as a risk factor Identification & Risk stratification The guidelines Choice of drugs Prescribing NOACs: practical aspects
19 Treatment guidelines European Cardiology Society Guidelines 2012 NICE guidelines June 2014 AWMSG guidelines September 2014
20 Anticoagulation for AF Risk category One major risk factor or 2 clinically relevant non-major risk factors One clinically relevant non-major risk factor CHA 2 DS 2 -VASc score 2 Recommended antithrombotic therapy Oral anticoagulant (OAC) 1 Oral anticoagulant No risk factors 0 No antithrombotic therapy European Heart Journal (2012) 33,
21 European Heart Journal (2012) 33,
22 Key points The importance of AF as a risk factor Identification & Risk stratification The guidelines Choice of drugs Prescribing NOACs: practical aspects
23 Warfarin is highly effective Warfarin better Placebo better AFASAK SPAF BAATAF CAFA SPINAF EAFT All trials RRR 64% *, ARR 2.7% (95% CI: 49 74%) RRR (%) Random effects model; Error bars = 95% CI; * p>0.2 for homogeneity; Relative risk reduction (RRR) for all strokes (ischaemic and haemorrhagic) Compared to a 19% RRR, 0.7% ARR for aspirin Hart RG et al. Ann Intern Med 2007;146: DBG2919 September 2011
24
25 Disadvantages of warfarin Narrow therapeutic index Slow onset of action Inter-individual (genetic) variabilty Need for regular monitoring Poor anticoagulation control in up to 45% Potentially dangerous interactions Poor compliance
26 % of patients without stroke IMPACT OF POOR INR CONTROL Stroke survival in 37,907 AF patients UK General Practice Research Database (27,458 warfarin users and 10,449 not treated with an antithrombotic) No warfarin I I I I I I Months %TTR > < 30 Adapted from Gallagher et al. Thromb Haemost 2011;106:
27 New anticoagulants: modes of action TF / VIIa x IX IXa VIIIa Va Xa Apixaban Edoxaban Rivaroxaban II IIa Dabigatran Fibrinogen Fibrin
28 Warfarin vs New oral anticoagulants Features Warfarin New drugs Onset Slow Rapid Dosing Variable Fixed Interaction with food Yes No Drug interaction Many Few Monitoring Yes No Half life Long Short Antidotes Yes Under evaluation
29 Features of new oral anticoagulants Features Rivaroxaban Apixaban Edoxaban Dabigatran Target Xa Xa Xa IIa Molecular weight (Daltons) Prodrug No No No Yes Bioavailability (%) Time to peak (hrs) Half life (hrs) Renal excretion(%)
30 Efficacy of NOACs vs Warfarin: Meta-analysis Ruff et al, Lancet 2014, 383:
31 NOACs vs Warfarin: Secondary efficacy & safety outcomes Ruff et al, Lancet 2014, 383:
32 Key points The importance of AF as a risk factor Identification & Risk stratification The guidelines Choice of drugs Prescribing NOACs: practical aspects
33 Need for regular follow up NOACs can cause serious bleeding Older people are more susceptible for ADRs Drug-interactions do occur & can be dangerous
34 What to check? Adherence Thrombo-embolic events Bleeding & other ADRs Concomitant drugs including over the counter
35 AF oral anticoagulation card Card can be downloaded in a printer-ready form from
36 What to check? Check UE, FBC, LFT Consider stopping or changing the drug, if problems Arrange date for next follow up (1, 3 or 6 months)
37 Choosing a NOVAC Consider: Risk vs benefit Age Renal function Body weight Co-medications taken by patient PPI to reduce risk for GI bleeding Educate patient on importance of strict adherence
38 C. Everett Koop 13th Surgeon General of the United States under President Ronald Reagan from 1982 to 1989 Drugs don t work in patients who don t take them
39 Stephen Wilkins 2014
40 Initiation of the treatment Adherence: components Implementation of the dosing regimen Discontinuation marks the end of therapy Persistence: the length of time between initiation & discontinuation
41 Persistence better with NOACs Patients newly initiated on rivaroxaban or warfarin Treatment persistence was significantly better with rivaroxaban than with warfarin (hazard ratio (HR) 0.66; 95% confidence interval: , P, ) Laliberte et al Curr Med Res Opin 2014;30:
42 Od vs Bd Dosing: predicted biological impact
43 Analyse the reason before switching! Simply switching to a NOAC will not necessarily improve adherence! Medication adherence is not solely a patient problem Reliable quantification of dosing errors can reveal patient-specific causes of non-adherence and point to individualized solutions
44 Methods to monitor adherence Self-report Pill counts Direct methods (Pharmacokinetics & Pharmacodynamics) Prescription and refill databases Electronic monitoring: gold standard
45 Smart packages ( eg; MEMS ) MEMS is a smart package in the form of a cap containing an electronic chip registering the time & date of each pill bottle opening Safe, un-intrusive (easy use), long lasting (battery) Adherence data are reliable and detailed Can easily be adapted to blister packs, inhalers, injectable,etc or for poly medication. Arnet et al Front Pharmacol 2013;4:26.
46 Significant interactions Dronedarone Avoid Dabigatran Ketoconazole, Itraconazole, Voriconazole, Posaconazole Avoid Dabigatran, Apixaban & Rivaroxaban HIV protease inhibitors Avoid Rivaroxaban Rifampicin, St John s wort, Carbamezepine, Phenytoin, Phenobarbital Avoid Dabigatran, Apixaban
47 Potential care models
48 A model for long term NOVAC management
49 Do NOACs need drug level monitoring? Drug levels monitoring may be clinically helpful: To ensure clearance of the drug in an emergency procedure To ensure compliance. In the cases of overdoses, renal impairment & bleeding, drug levels are unlikely to be helpful
50 Dabigatran: measuring coagulant effect aptt: At trough >2x ULN suggests excess bleeding risk dtt: at trough >200ng/ml 65s: excess bleeding risk Ecarin clotting time: at trough >2x ULN: excess bleeding risk
51 Prothrombin time as a predictor of bleeding Edoxaban: prolonged but no known relation with bleeding risk Rivaroxaban: prolonged & may indicate excess bleeding risk but local calibration required Apixaban & Dabigatran: cannot be used
52 Van Ryn et al Am J Med 2012;125:417
53 Idarucizumab for Dabigatran Reversal A monoclonal antibody fragment Binds dabigatran with an affinity 350 times as high as that observed with thrombin Binds free and thrombin-bound dabigatran and neutralizes its activity. Immediate and complete reversal of the anticoagulant effects of dabigatran without procoagulant effects in volunteers Pollack et al DOI: /NEJMoa
54 Idarucizumab for Dabigatran Reversal 5 g of intravenous idarucizumab Patients who had serious bleeding (51 group A) or required an urgent procedure (39 group B) Primary end point: the maximum percentage reversal of the anticoagulant effect of dabigatran within 4 hours (DTT/ECT) Pollack et al DOI: /NEJMoa
55 Idarucizumab for Dabigatran Reversal Among 68 patients with DTT and 81 with ECT at baseline, the median maximum percentage reversal was 100% (95% CI, 100 to 100) Normalized the test results in 88 to 98% of the patients, an effect that was evident within minutes Pollack et al DOI: /NEJMoa
56 Idarucizumab for Dabigatran Reversal Pollack et al DOI: /NEJMoa
57 Idarucizumab for Dabigatran Reversal Among 35 patients in group A who could be assessed, hemostasis, was restored at a median of 11.4 hours. Among 36 patients in group B who underwent a procedure, normal intraoperative hemostasis was reported in 33, and mildly or moderately abnormal hemostasis was reported in 2 patients and 1 patient, respectively. One thrombotic event occurred within 72 hours after idarucizumab administration in a patient in whom anticoagulants had not been reinitiated Pollack et al DOI: /NEJMoa
58 Anti-Xa reversal agents under development Andexanet alfa, a recombinant factor Xa variant that specifically binds all the oral factor Xa inhibitors but lacks coagulant activity. PER977, a nonspecific reversal agent, which binds to several of the direct oral anticoagulants by means of electrostatic interactions
59 Perioperative dosing of NOACs
60 The ambulance chasers are here! Xarelto causes serious injuries, compensation available - Click Here
61 Conclusions AF is an important risk factor for stroke & leads to severe strokes It is still under recognized & under treated Anticoagulation is highly effective in stroke prevention New anticoagulants offer a number of advantages over warfarin
AF, Stroke Risk and New Anticoagulants
Carmarthen Cardiac Update Course AF, Stroke Risk and New Anticoagulants Dr Hamsaraj Shetty, B.Sc, FRCP (London & Edinburgh) Consultant Physician & Honorary Senior Lecturer University Hospital of Wales,Cardiff
More informationLong term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial
Long term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial Camillo Autore Università di Roma Sapienza II Facoltà di Medicina e Chirurgia
More information4/9/2015. Risk Stratify Our Patients. Stroke Risk in AF: CHADS2 Scoring system JAMA 2001; 285: 2864-71
Anticoagulation in the 21 st Century Adam Karpman, D.O. Saint Francis Medical Center/Oklahoma State University Medical Center Disclosures: None Atrial Fibrillation Most common arrhythmia in clinical practice.
More informationNew Anticoagulation Options for Stroke Prevention in Atrial Fibrillation. Joy Wahawisan, Pharm.D., BCPS April 25, 2012
New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation Joy Wahawisan, Pharm.D., BCPS April 25, 2012 Stroke in Atrial Fibrillation % Stroke 1991;22:983. Age Range (years) CHADS 2 Risk
More informationNORTH WEST LONDON GUIDANCE ANTITHROMBOTIC MANAGEMENT OF ATRIAL FIBRILLATION
North West London CardioVascular & Stroke Network NORTH WEST LONDON GUIDANCE ON ANTITHROMBOTIC MANAGEMENT OF ATRIAL FIBRILLATION Key Messages 1. Efforts should be made to identify patients with Atrial
More informationSTROKE PREVENTION IN ATRIAL FIBRILLATION
STROKE PREVENTION IN ATRIAL FIBRILLATION OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention of ischemic stroke and arterial thromboembolism in patients
More informationXarelto (Rivaroxaban)
Xarelto (Rivaroxaban) Hightly selective, reversible, direct oral FXa inhibitor Maxium concentratiion after 2 to 4 hrs High bioavailability(66%),increase with food ( suggest with food) 1/3 from renal excretion,
More informationNOAC S For Stroke Prevention in. Atrial Fibrillation. Peter Cohn M.D FACC Associate Physician in Chief Cardiovascular Care Center Southcoast Health
NOAC S For Stroke Prevention in Atrial Fibrillation Peter Cohn M.D FACC Associate Physician in Chief Cardiovascular Care Center Southcoast Health New Oral Anti Coagulant Formal Definition: Atrial Fibrillation
More informationPerioperative Bridging in Atrial Fibrillation: Is it necessary?
Perioperative Bridging in Atrial Fibrillation: Is it necessary? Jason B. Thompson M.D., Ph.D. August 29, 2015 2015 NCVH Birmingham Hypothesis: When bridging, risk of bleeding < risk systemic embolism (SE).
More informationNew Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013
New Treatments for Stroke Prevention in Atrial Fibrillation John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013 Classification Paroxysmal atrial fibrillation (AF) Last < 7
More informationAnalyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation
Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation Drew Baldwin, MD Virginia Mason Seattle, Washington NCVH May 29,
More informationPrevention of thrombo - embolic complications
Update on atrial fibrillation Prevention of thrombo - embolic complications Felicita Andreotti Dept of Cardiovascular Science Catholic University, Rome, IT Consultant or speaker in past 2 years for Amgen,
More informationPrevention of stroke in patients with atrial fibrillation
www.sign.ac.uk Prevention of stroke in patients with atrial fibrillation A guide for primary care January 2014 Evidence Contents 1 Introduction... 1 2 Detection...2 3 Risk stratification... 3 4 Treatment
More informationNew Oral Anticoagulants. How safe are they outside the trials?
New Oral Anticoagulants How safe are they outside the trials? Objectives The need for anticoagulant therapy Indications for anticoagulation Traditional anticoagulant therapies Properties of new oral anticoagulants
More informationAtrial Fibrillation: Stroke and Thromboprophylaxis. Derek Waller
Atrial Fibrillation: Stroke and Thromboprophylaxis Derek Waller Atrial Fibrillation in the Elderly: Risk of Stroke Framingham study AGE 50-59 60-69 70-79 80-89 Prevalence of AF % Attributable Risk of AF
More information22-Oct-14. Oral Anticoagulation Which Drug for Which Patient in the era of New Oral Anti-coagulants. Atrial Fibrillation. AF as an embolic risk factor
Oral Anticoagulation Which Drug for Which Patient in the era of New Oral Anti-coagulants Dr Scott McKenzie BSc MBBS FRACP FCSANZ Cardiologist, Vascular Physician, Telehealth Specialist, Advanced Heart
More informationAdherence to NOACs. Disclosure. Patricia van den Bemt EAHP Hamburg 2015
Adherence to NOACs Patricia van den Bemt EAHP Hamburg 2015 Disclosure Unrestricted research grants from Glaxo-SmithKline Boehringer Ingelheim Daiichi Sankyo Bayer Pfizer For research on medication safety
More informationCardiology Update 2014
Cardiology Update 2014 Update on the Novel Oral Anticoagulants (NOACS) Raymond Kawasaki, MD AMG Cardiology December 6, 2014 Disclosures I have no disclosures relevant to this presentation Contents I. The
More informationSTROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND:
STROKE PREVENTION IN ATRIAL FIBRILLATION TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention
More informationTA 256: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation
Service Notification in response to DHSSPS endorsed NICE Technology Appraisals TA 256: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation 1 Name of Commissioning
More informationDorset Cardiac Centre
P a g e 1 Dorset Cardiac Centre Patients with Atrial Fibrillation/Flutter undergoing DC Cardioversion or Ablation procedures- Guidelines for Novel Oral Anti-coagulants (NOACS) licensed for this use February
More informationAnticoagulation For Atrial Fibrillation
Anticoagulation For Atrial Fibrillation New Agents In A New Era Arjun V Gururaj, MD Arrhythmia and Electrophysiology Nevada Heart and Vascular Center Disclosures Biotronik Speaker Clinical investigator
More informationAHA/ASA Scientific Statement Oral Antithrombotic Agents for the Prevention of Stroke in Atrial Fibrillation
AHA/ASA Scientific Statement Oral Antithrombotic Agents for the Prevention of Stroke in Atrial Fibrillation A Statement for Healthcare Professionals from the American Heart Association/American Stroke
More informationAtrial fibrillation: medicines to help reduce your risk of a stroke what are the options?
Patient decision aid Atrial fibrillation: medicines to help reduce your risk of a stroke what are the options? http://guidance.nice.org.uk/cg180/patientdecisionaid/pdf/english Published: June 2014 About
More informationKevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013
Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013 Family physician with Rivergrove Medical Clinic Practice in the north end since 1985 Medical Director of the Wellness
More informationGRASP-AF Coming to a PCT near you.
GRASP-AF Coming to a PCT near you. ADAS Anticoagulation dosing advisory service Blackpool Teaching Hospitals Trust Sean O'Brien; Anticoagulation Specialist BMS Grasp-AF and the implications on our Anticoagulation
More informationHow To Use Novel Anticoagulants In Cornwall
PENINSULA NETWORK GUIDANCE ON NOVEL ANTICOAGULANTS FOR STROKE AND TIA MANAGEMENT 1. Aim/Purpose of this Guideline The aim of this document to guide clinicians on use of novel anticoagulants for stroke
More informationSTARTING, SWITCHING OR STOPPING NEW ORAL ANTICOAGULANTS: A Practical Approach
STARTING, SWITCHING OR STOPPING NEW ORAL ANTICOAGULANTS: A Practical Approach Jeffrey I Weitz, MD, FRCP(C), FACP Professor of Medicine and Biochemistry McMaster University Canada Research Chair in Thrombosis
More informationRivaroxaban: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF
Leeds Rivaroxaban: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF Amber Drug Level 3 (amber drug with monitoring requirements) We have started your
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF)
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF) Key priorities Identification and diagnosis Treatment for persistent AF Treatment for permanent AF Antithrombotic
More informationThe author has no disclosures
Mary Bradbury, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Surgery September 18, 2012 Mary.bradbury@inova.org This presentation will discuss unlabeled and investigational use of products The author
More information3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin.
To Clot or Not What s New In Anticoagulation? Anita Ralstin, MS CNS CNP 1 Clotting Cascade 2 Anticoagulant drug targets Heparin XI VIII IX V X VII LMWH II Warfarin Fibrin clot 1 Who Needs Anticoagulation
More information1/12/2016. What s in a name? What s in a name? NO.Anti-Coagulation. DOACs in clinical practice. Practical aspects of using
What s in a name? Practical aspects of using DOACs (Direct Oral Anticoagulants) James L. Sebastian, MD, MACP Professor of Medicine (GIM) Medical College of Wisconsin February 5, 2016 DOAC NOAC NOAC ODI
More informationThrombosis management: A time for change practical management with NOACs Dr Wala Elizabeth Medical Director, Bayer Healthcare
Thrombosis management: A time for change practical management with NOACs Dr Wala Elizabeth Medical Director, Bayer Healthcare Kenya Association of Physicians Conference 10 th May 2013 New anticoagulants:
More informationThree new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008:
Key Points to consider when prescribing NOACs Introduction Three new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008: Dabigatran Etexilate (Pradaxa ) 75mg, 110mg, 150mg. Rivaroxaban
More informationAnticoagulation before and after cardioversion; which and for how long
Anticoagulation before and after cardioversion; which and for how long Sameh Samir, MD Cardiovascular medicine dept. Tanta faculty of medicine Atrial fibrillation goals of management Identify and treat
More informationSpeaker Disclosure. Outline. Pharmacist Objectives. Patient Case. Outline 9/4/2014
Speaker Disclosure Matthew K. Pitlick, Pharm.D., BCPS St. Louis College of Pharmacy/VA St. Louis HCS mpitlick@stlcop.edu Matthew K. Pitlick, Pharm.D., BCPS declares no conflicts of interest, real or apparent,
More informationAnticoagulants in Atrial Fibrillation
Anticoagulants in Atrial Fibrillation Starting and Stopping Them Safely Carmine D Amico, D.O. Overview Learning objectives Introduction Basic concepts Treatment strategy & options Summary 1 Learning objectives
More informationNIL. Dr Chuks Ajaero FMCP FRACP Cardiologist QEH, NALHN, SA Heart & Central Districts. Approach. Approach. 06-Nov-14
Stroke Prevention in Atrial Fibrillation: Commencing Non- Oral Anticoagulants in GP setting Dr Chuks Ajaero FMCP FRACP Cardiologist QEH, NALHN, SA Heart & Central Districts Disclosures NIL Classification
More informationDabigatran (Pradaxa) Guidelines
Dabigatran (Pradaxa) Guidelines Dabigatran is a new anticoagulant for reducing the risk of stroke in patients with atrial fibrillation. Dabigatran is a direct thrombin inhibitor, similar to warfarin, without
More informationNovel Anticoagulation Agents DISCLOSURES. Objectives ATRIAL FIBRILLATION TRIALS. NOAC Comparison 6/12/2015
Novel Anticoagulation Agents DISCLOSURES James W. Haynes, MD Department of Family Medicine Univ of TN Health Science Center (Chattanooga) Objectives Understand mechanism of action behind the NOAC agents
More informationNew anticoagulants: Monitoring or not Monitoring? Not Monitoring
The 2 nd World Congress on CONTROVERSIES IN HEMATOLOGY (COHEM) Barcelona, Spain September 6 8, 2012 New anticoagulants: Monitoring or not Monitoring? Not Monitoring Anna Falanga, MD Immunohematology and
More informationNovel OAC s : How should we use them?
Novel OAC s : How should we use them? Jean C. Grégoire MD, FRCP(c), FACC, FACP Associate Professor, Université de Montréal, IntervenJonal Cardiologist, InsJtut de cardiologie de Montréal Disclosures Speaker
More informationGoals 6/6/2014. Stroke Prevention in Atrial Fibrillation: New Oral Anti-Coagulants No More INRs. Ashkan Babaie, MD
Stroke Prevention in Atrial Fibrillation: New Oral Anti-Coagulants No More INRs Ashkan Babaie, MD Arrhythmia Service Providence Heart Clinic June 8 th, 2014 Goals Discuss the data behind approval of NOACs
More informationCurrent and new oral Anti-coagulation. Lancashire and Cumbria Network 2 February 2012
Current and new oral Anti-coagulation Lancashire and Cumbria Network 2 February 2012 Question Warfarin is an abbreviation What does the W stand for? What is this plant and what is the connection with warfarin?
More informationAll Wales Risk/Benefit Assessment Tool for Oral Anticoagulant Treatment in People with Atrial Fibrillation
All Wales Risk/Benefit Assessment Tool for Oral Anticoagulant Treatment in People with Atrial Fibrillation October 2013 This report has been prepared by a multiprofessional collaborative group, with support
More informationPost-ISTH review: Thrombosis-I New Oral Anticoagulants 臺 大 醫 院 內 科 部 血 液 科 周 聖 傑 醫 師
Post-ISTH review: Thrombosis-I New Oral Anticoagulants 臺 大 醫 院 內 科 部 血 液 科 周 聖 傑 醫 師 The antithrombotic efficacy is limited but the risk of bleeding is indefinite Fuster V et al. Circulation 2011;123:e269-e367
More informationAnticoagulation at the end of life. Rhona Maclean Rhona.maclean@sth.nhs.uk
Anticoagulation at the end of life Rhona Maclean Rhona.maclean@sth.nhs.uk Content Anticoagulant Therapies Indications for anticoagulation Venous thromboembolism (VTE) Atrial Fibrillation Mechnical Heart
More informationPHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES.
PHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES. Hossam Bahy, MD (1992 2012), 19 tools have been identified 11 stroke scores 1
More informationNHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation
NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation Date of First Issue 06/06/2012 Approved 06/06/2012 Current Issue Date 29/10/2014 Review Date 29/10/2016 Version 1.4 EQIA Yes 01/06/2012
More informationTime of Offset of Action The Trial
New Antithrombotic Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant Amgen Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University What I am Talking About
More informationThe 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era. CCRN State of the Heart 2012 June 2, 2012
The 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era CCRN State of the Heart 2012 June 2, 2012 Disclosures I have I have been involved in trials of new anticoagulants and have received
More informationHERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below
Name: generic (trade) Rivaroxaban (Xarelto ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below What it is Indications
More informationPrescriber Guide. 20mg. 15mg. Simply Protecting More Patients. Simply Protecting More Patients
Prescriber Guide 20mg Simply Protecting More Patients 15mg Simply Protecting More Patients 1 Dear Doctor, This prescriber guide was produced by Bayer Israel in cooperation with the Ministry of Health as
More informationAtrial Fibrillation An update on diagnosis and management
Dr Arvind Vasudeva Consultant Cardiologist Atrial Fibrillation An update on diagnosis and management Atrial fibrillation (AF) remains the commonest disturbance of cardiac rhythm seen in clinical practice.
More informationNHS DORSET CLINICAL COMMISSIONING GROUP POSITION STATEMENT ON ORAL ANTICOAGULANTS IN ATRIAL FIBRILLATION
Version 3 August 2014 NHS DORSET CLINICAL COMMISSIONING GROUP POSITION STATEMENT ON ORAL ANTICOAGULANTS IN ATRIAL FIBRILLATION Dorset CCG commissions the use of newer oral anti-coagulants in accordance
More informationAppendix C Factors to consider when choosing between anticoagulant options and FAQs
Appendix C Factors to consider when choosing between anticoagulant options and FAQs Choice of anticoagulant for non-valvular* atrial fibrillation: Clinical decision aid Patients should already be screened
More informationDabigatran: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF
Leeds Dabigatran: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF Amber Drug Level 3 (amber drug with monitoring requirements) We have started your
More informationHow To Treat Aneuricaagulation
Speaker Introduction Jessica Wilhoite, PharmD, BCACP Doctor of Pharmacy: Purdue University Postgraduate Residency Training: PGY1 Pharmacy Practice St. Vincent Hospital PGY2 Ambulatory Care St. Vincent
More informationDISCLOSURES CONFLICT CATEGORY. No conflict of interest to disclose
DISCLOSURES CATEGORY Employment Research support Scientific advisory board Consultancy Speakers bureau Major stockholder Patents Honoraria Travel support Other CONFLICT No conflict of interest to disclose
More informationAntiplatelet and Antithrombotic Therapy. Dr Curry Grant Stroke Prevention Clinic Quinte Health Care
Antiplatelet and Antithrombotic Therapy Dr Curry Grant Stroke Prevention Clinic Quinte Health Care Disclosure of Potential for Conflict of Interest Dr. F.C. Grant Atrial Fibrillation FINANCIAL DISCLOSURE:
More informationThe Anticoagulated Patient A Hematologist s Perspective
The Anticoagulated Patient A Hematologist s Perspective Deborah M. Siegal MD MSc FRCPC Clinical Scholar Division of Hematology and Thromboembolism Thrombosis Canada Research Fellow McMaster University
More informationComparison between New Oral Anticoagulants and Warfarin
Comparison between New Oral Anticoagulants and Warfarin Warfarin was the mainstay of oral anticoagulant therapy until the recent discovery of more precise targets for therapy. In recent years, several
More informationOAC and NOAC with or without platelet inhibition
Zürich 11.06.2015 Preoperative antithrombotic management OAC and NOAC with or without platelet inhibition Miodrag Filipovic miodrag.filipovic@kssg.ch Anästhesiologie & Intensivmedizin Case 1 76 yr old
More informationNew therapeutic approaches for the protection of AF patients from stroke: Do aspirin or warfarin have a role anymore?
New therapeutic approaches for the protection of AF patients from stroke: Do aspirin or warfarin have a role anymore? Dr Tina Biss Consultant Haematologist The Newcastle Hospitals NHS Foundation Trust
More informationrivaroxaban 15 and 20mg film-coated tablets (Xarelto ) SMC No. (756/12) Bayer PLC
rivaroxaban 15 and 20mg film-coated tablets (Xarelto ) SMC No. (756/12) Bayer PLC 13 January 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS
More informationNow We Got Bad Blood: New Anticoagulant Reversal
Now We Got Bad Blood: New Anticoagulant Reversal Kellie Rodriguez, PharmD, BCPS PGY2 Emergency Medicine Pharmacy Resident UF Health Jacksonville January 2016 Objectives 1. Review current treatment strategies
More informationNew Anticoagulants: Are we Ready to Replace Warfarin? Carole Goodine, RPh Horizon Health Network Stroke Conference 2011
New Anticoagulants: Are we Ready to Replace Warfarin? Carole Goodine, RPh Horizon Health Network Stroke Conference 2011 Warfarin Decreases stroke risk by 60-70% Superior to ASA and ASA plus clopidogrel
More informationDOACs. What s in a name? or TSOACs. Blood Clot. Darra Cover, Pharm D. Clot Formation DOACs work here. Direct Oral AntiCoagulant
DOACs NOACs or TSOACs Generic Name DOACs Brand Name Mechanism of Action Direct Xa Inhibitor Direct Thrombin Inhibitor Dabigatran Pradaxa X Rivaroxaban Xarelto X Darra Cover, Pharm D Apixaban Eliquis X
More informationThe Role of the Newer Anticoagulants
The Role of the Newer Anticoagulants WARFARIN = Coumadin DAGIBATRAN = Pradaxa RIVAROXABAN = Xarelto APIXABAN = Eliquis INDICATION DABIGATRAN (Pradaxa) RIVAROXABAN (Xarelto) APIXABAN (Eliquis) Stroke prevention
More informationStroke Prevention in Atrial Fibrillation. NICE guidelines 2014 and their local implementation
Stroke Prevention in Atrial Fibrillation NICE guidelines 2014 and their local implementation Craig Barr Consultant Cardiologist Prescribing information available at this meeting L.GB.09.2014.7880c Date
More informationAtrial Fibrillation: A Different Perspective. Michael Heffernan MD PhD FRCPC FACC Staff Cardiologist Oakville Hospital
Atrial Fibrillation: A Different Perspective Michael Heffernan MD PhD FRCPC FACC Staff Cardiologist Oakville Hospital Faculty/Presenter Disclosure Faculty: Dr. Michael Heffernan Relationships with commercial
More informationHow To Understand How The Brain Can Be Affected By Cardiac Problems
Workshop 2e: Atrial Fibrillation, Heads and Hearts how the brain can be affected by cardiac problems Matthew Walters Heads and Hearts Cardiac disease and stroke Matthew Walters University of Glasgow Why
More informationNHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation
NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation Date of First Issue 06/06/2012 Approved 06/06/2012 Current Issue Date 06/06/2012 Review Date 06/06/2014 Version 1.1 EQIA Yes /
More informationTranslating clinical evidence into real-world outcomes
Annual Swiss Stroke Society Meeting 31st of January 2013 Symposium: From RE-LY to practice: Changing the attitude on stroke prevention in AF Translating clinical evidence into real-world outcomes Unité
More informationNovel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations
Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations Dardo E. Ferrara MD Cardiac Electrophysiology North Cascade Cardiology PeaceHealth Medical Group Which anticoagulant
More informationRivaroxaban A new oral anti-thrombotic Dr. Hisham Aboul-Enein Professor of Cardiology Benha University 12/1/2012
Rivaroxaban A new oral anti-thrombotic Dr. Hisham Aboul-Enein Professor of Cardiology Benha University 12/1/2012 Agenda Ideal anticoagulant. Drawbacks of warfarin. Rivaroxaban in clinical trails. Present
More informationWhat to do in case of hemorragia. L Camoin Jau Service d Hématologie APHM Marseille
What to do in case of hemorragia with NOAC? L Camoin Jau Service d Hématologie APHM Marseille Disclosure Boehringer Bayer Daishi Sanofi BMS Pharmacodynamic and kinetic properties of new oral anticoagulants.
More informationThe New Oral Anticoagulants: When and When Not to Use Them Philip C. Comp, M.D., Ph.D. Professor of Medicine, University of Oklahoma Health Sciences
The New Oral Anticoagulants: When and When Not to Use Them Philip C. Comp, M.D., Ph.D. Professor of Medicine, University of Oklahoma Health Sciences Center September 25, 2015 Question: With which of the
More informationLaboratory Testing in Patients on Novel Oral Anticoagulants (NOACs)
Laboratory Testing in Patients on Novel Oral Anticoagulants (NOACs) Dr. Art Szkotak artur.szkotak@albertahealthservices.ca University of Alberta Hospital Edmonton, AB NOACs Direct Thrombin Inhibitors (DTI):
More informationAnticoagulation - which patients should be on Novel Oral Anticoagulants (NOAC)?
Anticoagulation - which patients should be on Novel Oral Anticoagulants (NOAC)? Welsh Primary Cardiovascular Conference Abertawe, Mai 2014 Gethin Ellis Cardiologist Cwm Taf UHB Declaration (?conflicts)
More informationNew Anticoagulants: When and Why Should I Use Them? Disclosures
Winship Cancer Institute of Emory University New Anticoagulants: When and Why Should I Use Them? Christine L. Kempton, MD, MSc Associate Professor of Pediatrics and Hematology and Medical Oncology Hemophilia
More informationAnticoagulation: How Do I Pick From All the Choices? Jeffrey H. Neuhauser, DO, FACC BHHI Primary Care Symposium February 28, 2014
Anticoagulation: How Do I Pick From All the Choices? Jeffrey H. Neuhauser, DO, FACC BHHI Primary Care Symposium February 28, 2014 Atrial Fibrillation 2 Atrial Fibrillation The most common arrhythmia encountered
More informationNICE clinical guideline 180: Atrial fibrillation Prescribing and medicines optimisation issues
NICE clinical guideline 180: Atrial fibrillation Prescribing and medicines optimisation issues Andy Hutchinson Medicines Education Technical Adviser NICE Medicines and Prescribing Centre Note: this is
More informationAnticoagulation in Atrial Fibrillation
Anticoagulation in Atrial Fibrillation Parag P. Patel, MD FACC Disclosures Eliquis Speakers Bureau 1 Clinical Scenario Ms. L is a 76F admitted to the stroke service with a dense right sided hemiparesis
More informationThe New Anticoagulants are Here! Do you know how to use them? Arrhythmia Winter School February 11 th, 2012. Jeff Healey
The New Anticoagulants are Here! Do you know how to use them? Arrhythmia Winter School February 11 th, 2012 Jeff Healey RELY: A New Era in AF Connolly SJ et al. N Engl J Med 2009;361:1139-1151 ROCKET-AF:
More informationCOMPARISON OF NEW ORAL ANTICOAGULANTS AND FREQUENTLY- ASKED QUESTIONS FROM PATIENTS. TARGET AUDIENCE: All Canadian health care professionals.
COMPARISON OF NEW ORAL ANTICOAGULANTS AND FREQUENTLY- ASKED QUESTIONS FROM PATIENTS AND PHYSICIANS TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVES: To provide a comparison of the new
More informationDVT/PE Management with Rivaroxaban (Xarelto)
DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular
More information1/7/2012. Objectives. Epidemiology of Atrial Fibrillation(AF) Stroke in AF. Stroke Risk Stratification in AF
Objectives Atrial Fibrillation and Prevention of Thrombotic Complications: Therapeutic Update Andrea C. Flores Pharm.D Pharmacy Resident at the Miami VA Healthcare System Review the epidemiology, pathophysiology
More informationFOR THE PREVENTION OF ATRIAL FIBRILLATION RELATED STROKE
www.bpac.org.nz keyword: warfarinaspirin FOR THE PREVENTION OF ATRIAL FIBRILLATION RELATED STROKE Key Concepts In atrial fibrillation (AF) warfarin is more effective than aspirin for stroke prevention.
More informationNew Anticoagulants. Stroke Prevention in AF Commencing Novel Oral Anticoagulants (NOACs) in the GP Setting. 30-Oct-14
Stroke Prevention in AF Commencing Novel Oral Anticoagulants (NOACs) in the GP Setting A/Prof Michael Nguyen Fremantle Hospital Access Cardiology General Practice Education Day Oct 2014 ORAL TTP889 Rivaroxaban
More informationNICE TA 275: Apixaban for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation
Service Notification in response to DHSSPS endorsed NICE Technology Appraisals NICE TA 275: Apixaban for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation 1
More informationAtrial Fibrillation: New Therapies for an Old Problem
Atrial Fibrillation: New Therapies for an Old Problem Nguyen Park, MS, PA-C UNM Physician Assistant Program Dept. of Family & Community Medicine Univesity of New Mexico Lead Clinician Special Environmental
More informationEast Kent Prescribing Group
East Kent Prescribing Group Rivaroxaban (Xarelto ) Safety Information Approved by the East Kent Prescribing Group. Approved by: East Kent Prescribing Group (Representing Ashford CCG, Canterbury and Coastal
More informationThe management of cerebral hemorrhagic complications during anticoagulant therapy
The management of cerebral hemorrhagic complications during anticoagulant therapy Maurizio Paciaroni Stroke Unit Division of Cardiovascular Medicine University of Perugia - Italy Perugia Stroke Registry
More informationHow To Compare Warfarin To Dabigatran
Page 1 WOMEN AT RISK Anticoagulation Issues In Atrial Fibrillation WOMEN AT RISK Anticoagulation Issues In Atrial Fibrillation J E A N N A P P I, P H A R M. D., F C C P, B C P S Accreditation: Pharmacists:
More informationBirmingham, Sandwell and Solihull Cardiac and Stroke Network. Rivaroxaban or warfarin for treatment of Atrial Fibrillation: Position statement
Birmingham, Sandwell and Solihull Cardiac and Stroke Network Rivaroxaban or warfarin for treatment of Atrial Fibrillation: Position statement Introduction This guidance informs prescribers and commissioners
More informationManagement of atrial fibrillation. Satchana Pumprueg, MD Sirin Apiyasawat, MD Thoranis Chantrarat, MD
Management of atrial fibrillation Satchana Pumprueg, MD Sirin Apiyasawat, MD Thoranis Chantrarat, MD Antithrombotic therapy in atrial fibrillation Satchana Pumprueg, MD AF has serious consequences Independent
More information9/5/14. Objectives. Atrial Fibrillation (AF)
Novel Anticoagulation for Prevention of Stroke in Patients with Atrial Fibrillation Objectives 1. Review current evidence on use of warfarin in individuals with atrial fibrillation 2. Compare the three
More informationTraditional anticoagulants
TEGH Family Practice Clinic Day April 4, 03 Use of Anticoagulants in 03: What s New (and What Isn t) Bill Geerts, MD, FRCPC Director, Thromboembolism Program, Sunnybrook HSC Professor of Medicine, University
More information